family of receptor subtypes, defined either by molecular (mlm5) or pharmacological (MLM4) analysis. mediates muscarinic cholinecgic neurotransmission in brain. The distribution and functions of the m3 receptor protein in brain and its relation to M3 ligand binding sites are poorly undersrood. To better characterize the native brain receptors. subtype-specific antibodies reactive with the putative third inner loops were used: (i) to measure the abundance of m3 protein and its regional distribution in rat brain by immunoprecipitation; (ii) to determine the cellular and subcellular distribution of m3 protein by light microscopic immunocytochemistry; and (iii) to compare the dist~bution of m3 immunorea~tIvity with the autoradiographic dist~bution of M3 binding sites labeled by [3~]4-diphenylacetoxv-~-methy1 piperidine methioxide in the presence of antagonists selective for the other receptor binding Ltes. The m3 protein, measured by immunoprecipitation, accounted for 5-10% of total solubilized receptors in all brain regions studied. lmmunocytochemistry also revealed a widespread distribution of m3-like immunoreactivity, and localized the subtype to discrete neuronal populations and distinct subceliular compartments. The distribution of m3 protein was consistent with the messenger RNA expression, and like M3 binding sites, the protein was enriched in limbic cortical regions, striatum, hippocampus, anterior thalamic nuclei, superior colliculus and pontine nuclei. However, m3 immunoreactivity and M3 binding were differentially localized in regions and lamina of cortex and hippocampus.
Muscarinic acetylcholine receptor subtypes mediate diverse cholinergic effects in brain and other tissues. The subtypes are classified either pharmacologically by differential binding affinities for antagonists (M1-M4)36 or genetically by direct sequence analysis (m1-m5).2~",Z6 The use of two classification schemes and a variety of methods for identification of receptor binding sites, mRNA and proteins have led to considerable uncertainty regarding the distributions and functions of the subtypes. A general correspondence between Ml-M4 binding sites and the respective ml-m4 gene products (proteins) has been suggested,s~"~z2~3y based largely on the binding affinities of the cloned receptors. However, the subtypes have a high degree of sequence homology in the putative transmembrane domains where ligand bind--..~~~ *To whom correspondence should be addressed.
Abbreviations:
AF-DX 116, 1 I-([2-((diethylamino)methyl}-I-piperidinyljacetyl-S,I I-dihydro-6H-pyrido~, 3-b] [l,4]-ben~dizepine-6-on~ &DAMP, 4-dip~n~rlacetoxy.~~ methylpiperidine methioxide; NMS, N-methylscapolamine; TE, Tris-EDTA buffer; TED, Tris-EDTAdigitonin buffer.
ing occurs," making development of more highly selective drugs for ml-m5 difficult.4,b For this reason. the relationships between native binding sites in brain and the molecularIy distinguish~ proteins are uncertain.'6. '9 Methodological improvements for receptor localization, including autoradiography with more selective ligands and immun~yt~hem~st~ with subtype-selective antibodies, have begun to clarify the distributions of the subtypes and the degree of correspondence between the classification systems. Ml sites defined pha~acologi~lly by ~gh-a~nity binding of pirenzepine and related compounds,9.B and ml protein measured by immunoprecipitation,'6 'p,37 are both present at highest levels in neocortex, hippocampus and striatum? with much lower levels in thalamus and other hindbrain structures. Immunocytochemical studies have recently localized ml to postsynaptic sites on the somata and dendrites of most neurons in cortex, hip~ampus and striatum.*0~'6~i4 M2 sites defined pha~acolo~i~ally by low affinity with pirenzepine and high affinity with AF-DX 116 and other compounds,",36,'y and m2 207 pr&ein measured by ~mmunoprecipltation'"'" are both widespread in brain. Immunccytochcmical studies have more precisely localized m2 to cbolinergic and non-cholinergic neurons and both yre-and postsynaptic sites. i",1S,24 Although these comparisons show a general agreement in the distributions of Vl1
and ml, and M2 and m2, the other subtypes compl.icate this apparent correspondence. Fnr example. the m4 protein is abundant in forebrain regions and likely contributes TV both Ivli and M? binding sites."*" Indeed, m3, 124 and n-15 all have intermediate birlding aRinities for Ml-and MZ-prrferklg ligandsT6 and the distributmns of the mRNA and/or proteins overlap with the other muscarinie proteins, DitSiculry measuring and visualizing non-MljM2 and non-mfjm2 subtypes by both autoradiography and tmmunocytochemistry has precluded further comparisons. Recentfy, independent methods for Iocalizing %I\13 birding sites and m3 receptor immunoreactivity have been developed. Znhieta and I%$" described receptor autoradiographic techniques using [%]4-DAMP in the presence of unlabeled pirenzepine and AF-DX It6 to visualize M3 binding sites sekcti~ly in a wide distribution in brain. Subtype-specific antibodies reactive with m3 protein have been developed in our k&oratory" and others,?' and although the protein has been detected by irnrnunoprffipitation, the precise regional and cel!ular distribution of m3 in brain has not been described using immunocgtochernicai methods. The goals of the present study were to further investigate the distributions r>i' ITI? hy immunnprecipitation and immunncyt4xhemistr~, and to compare these findings with the distribution of M3 binding siterr.
EXPERIMENTAL FROCFLWRES
Antisera and affinity-purified rabbit poly&nal antibodies reactive with the putative third intracellular loops of the m3 receptor were generated and characterized previousIj'1"'7 This region is highly divergent among aft muscarinic and other identified reoeptors. In specificity tests using he using the avidin-biotin-peroxidase method (Elite, Vector Labs), and developed with diaminobenzidine hydrochloride as described previously.'6 Some sections from two tats were pretreated with hydrogen peroxide and sodium hydroxide to quench endogenous peroxidase and enhance antigen retrieval as described.' Affinity-purified antibodies to m3 were used at a final concentration of 0.5-l .O pg/ml; this dilution was chosen to optimize the signal-to-noise ratio. Immunocytochemical controls consisted of adsorption of the receptor antibodies with 100 pgjml of immobilized-GST or m3i?-GST fusion proteins, and omission of the primary antibody.
Autoradiographic ligand binding studies
Three male rats (Harlan Sprague-Dawley, Indianapolis, IN) were killed by decapitation, and the brains rapidly removed and frozen in crushed dry ice. Specimens were covered with embedding medium (Lipshaw, Detroit, MI) and stored at -70°C. Quadruplicate, corona1 brain sections (20 pm) were obtained with the use of a cryostat microtome at -18°C. Two adjacent sections at each level were mounted on each of two gelatin-subbed microscope slides, thaw-mounted and allowed to dry at room temperature. Slides were then stored at -70°C until use in binding assays. Autoradiographic binding assays were performed as described previously. 43 Slides were washed in buffer to remove endogenous interfering substances, incubated in the presence of 5 nM[jH]4-DAMP (82.6 Ci/mmol) for 60 min to label muscarinic receptors, followed by two successive 1 min incubations in fresh buffer at 4°C to remove non-specific binding. Slides were then dipped briefly in cold distilled water to remove excess buffer salts and allowed to air-dry At each anatomic level. one slide was prepared for evaluation of total 4-DAMP binding, as described above, while the second slide was processed to enhance the relative contribution of M3 receptors. This was accomplished by the addition of 1 ,IJM concentrations of unlabeled AF-DX 116 and pirenzepine to the 13H]4-DAMP incubation. This protocol results in 95% reductions in the binding of 4. DAMP to Ml and M2 receptors, while labeling 40% of the M3 receptors; in a hypothetical region conraining equal admixtures of Ml, M2 and M3 receptors, 85% of 4-DAMP binding under these conditions is attributable to the M3 sites. Autoradiograms were generated by apposition of slides to tritium-sensitive X-ray film (Hyperfilm-3H, Amersham, Arlington Heights, IL) for four weeks. Autoradiographic images were analysed with the use of a computer-assisted video densitometer (MCID system, Imaging Research, St Catherines, Ontario). 
RESULTS

Immunoprecipitation assay of muscarinic receptors
Saturation analyses of [3H]NMS binding to solubilized muscarinic receptors from whole brain were consistent with a homogeneous population of binding sites in each of three independent assays when analysed individually, and again in combination ( Fig. 1) . The estimated equilibrium dissociation constant was 0.30 + 0.03 nM (mean) SD.), with Hill coefficients ranging between 0.85 and 0.96. On this basis, 10 nM ['HINMS was chosen to provide essentially complete saturation of solubilized receptors for immunoprecipitation studies. This concentration of radioligand resulted in somewhat higher but acceptable levels of background compared to previous studies using 1 nM [3H]NMS,'6 with nonspecific trapping of ('H]NMS averaging 19% of total specific solubilized receptors added to each assay (ranging from 13% in striatum to 23% in ventral midbrain). There were no significant differences in background levels with non-immune sera or different control antisera to dopamine receptors and other brain proteins. This indicates that variations in the immunoglobulin concentrations as occurs among different antisera do not influence recovery of muscarinic receptor subtypes.
Other factors potentially affecting the immunoprecipitation assay were also analysed. Dissociation of ['HINMS from receptors during the itnmunoprecipitation process might occur due to antibody binding, washing or other reasons. To test these possibilities, solubilized receptors were incubated in 13H]NMS, followed by determination of bound activity by gel filtration. Addition of specific antisera or 10 PM atropine for up to 60min following the labeling of receptors did not reduce the recovery of specifically-bound activity as determined by gel filtration. Thus, it is unlikely that appreciable amounts of NMS dissociate during the imtnunoprecipitation procedure. Since solubilization efficiencies averaged 49%, we also investigated the possible fate of muscarinic receptors identified in the initial 
Itnmunoprf cipifation of m 3 m ral brain
Immunoprecipitation studies were used to determine the abundance of m3 receptor in various regions of rat brain, as shown in Table I . Precipitation of this subtype accounted for S-12% of the total number of solubilized i3H]NMS binding sites. Although these levels were relatively low, the immunoprecipitates with m3 antisera yielded significantly greater ['H]NMS recovery than control precipitates using non-immune sera for every region (P < 0.05, Student's t-test). The smallest relative difference between m3 and control immunoprecipitates was in frontal cortex (m3 was 21% higher than controls) and the largest difference in ventral midbrain (m3 was 53% higher than controls).
AS mentioned above, the use of different control antisera did not influence the results. The dis~~bution among dissected regions was also fairly uniform, with estimates of the tissue densities (corrected for solubilization efficiencies) ranging from 0.04 pmol/mg membrane protein in midbrain and thalamus to 0.09 pmol/mg in striatum.
The composition and relative abundance of the entire family of muscarinic receptors in rat brain are shown in Table 2 . Recovery of muscarinic receptor subtypes was close to 100%, based on the sum of the immunoprecipitates.
In frontal cortex and hippocampus, ml, m2 and m4 were the most abundant subtypes and each accounted for roughly onequarter to one-third of the total population of soiubilized [3H]N~S binding sites. In str~atum, the m4 subtype alone accounted for nearly one-half of the total receptors, whereas in thalamus and midbrain m2 was the most abundant subtype. The m5 receptor was recovered at low levels in every brain region, and was statistically significant compared to controk (P < 0.05) in every case except in ventral midbrain.
Light microscopic u'istribution of m3 immunoreacti~it.v in rut brain
The immunocytochemica1 distribution of m3 was widespread in rat brain, as shown in the right cofumn of Fig. 2 . In general, the microscopic appearance of the diaminobenzidine peroxidase reaction product was brown and finely granular, and associated with cell bodies, neuritic processes and neuropil. The density of the reaction product was routinely much less than as described previously for ml. m2 and m4. 16 Sections pretreated with hydrogen peroxide and sodium hydroxide exhibited moderately improved sensitivity compared to untreated sections. Immunological specificity was demonstrated by inhibition of staining after pr~~dsorption of the antisera with the i3 loop fusion protein, Control sections with omission of m3 antibody were routinely performed and showed light diamino~nzi~ne reaction product in occasionaf gfia, select neurons and a few other structures that in most cases were easily distinguished from antibody-treated sections; exceptions will be further described. Glial immunoreactivity with m3 antibody was frequently detected, but because this staining was usually light and occasionalfy present in control sections, it is diEcult to be certain if this represented specific reaction product. The same is true of blood vessels, which were frequently associated with immunoreactive fibers. Other descriptions of m3 immunoreactivity refer to specific staining not observed in controfs, with the intent that the term denotes m3 "like" jmmunoreactivity.
As with any immunocytochemical procedure, it is not possible to be certain that the reaction product is localized only to the m3 receptor in tissue sections, despite rigorous characterization of antibody specificity by immunoprecipitatjon and immunoblotting.
Cortical and reiated structures.
In the olfactory bulb, m3 immunoreactivity was enriched diffusely in the glomeruli and moderately in the external plexiform layer. In the cerebral cortex, m3 immunoreactivity was differentially distributed across regions and lamina (Figs 2, 3) . Limbic regions exhibited highest levels in cortex, including cingulate (Fig. 3D) . retrosplenial, piriform (Fig. 3E), entorhinal (Fig. 4 ) and insula and deep endopiriform cortex in the perirhinal region (Fig. 2) . lmmunoreactivity was most dense in the neuropil in the superficial aspect of the mofecular layer, and in neurons and the neuropi1 in layers II/III and V (Fig. 3) . Some astrogliaf processes also appeared lightly stained (see above). Neuropif immunoreactivity was mostly diffuse, but also associated with fine neurites and puncta. In the hipp~mpaf formation, entorhinal cortex (particularIy layer II cell islands and layer V neurons/ neuropil) and subiculum were prominently stained. In hippocampus proper, cell bodies and proximal dendrites of many pyramidal neurons and occasionally interneurons were lightly immunoreactive, with more intense diffuse and pun&ate immunoreactiv~ty in the neuropif in the stratum lacunosum moleculare, deep aspects of the stratum radiatum and stratum oriens, with CA3 greater than CA1 (Fig. 4) . In the dentate gyrus, neuropil immunoreactivity was most dense in the superficial molecular layer and the hilus, with little immunoreactjvity in the granule celfs. Amygdafa nuclei with the most dense m3 immunoreactivity were the basofateral and central nuclei (Fig. 3F) .
Subcortical forebrain
structures. The slriatum displayed among the highest densities of m3 immunoreactivity in brain (Figs 2, 3F ). Diffuse and finely punctate neuropif immunoreactivity were present throughout dorsal striatum, nucleus accumbcns and olfactory tubercle, and in some cases appeared patchy. Striataf neurons were rarely stained, and then only very lightly. In the basal forebrain (Fig. 4D) . immunoreactive neurons, proximal processes and puncta were present in the medial septum. nuclei of the diagonal band of Broca, ventral palfidum. prcoptic nuclei and nucleus basalis. While many of the large basal forebrain neurons were also lightly stained in control sections (Fig. 4E) , m3-treated sections consistently yielded more intense staining of these neurons. The dorsofateral septum had diffuse neuropil m3 ~mmunor~~ctivity. The gfohus paflidus. entopeduncular nucleus and substantia nigra contained abundant neurites and puncta, and also scattered neurons that were lightly stained. Subthalamus neurons were enriched in m3 immunoreactivity compared to most other basal ganglia nuclei (Fig. 5E) .
Diencephalon. The anteroventral, anteromedial and anterodorsal nuclei displayed the most intense m3 staining among thalamic nuclei and possibly other brain regions (Fig. 54 ). Neurons were prominent in the ~nterodorsal nucleus and the medial aspect of the anteroventral nucleus, while dense punctatc immunoreactivity was observed in the lateral aspect of the anteroventraf nucleus. Moderate levels of cellular immunoreactivity were present in lateral and medial geniculate, ventrobasai. mediodorsal. laterodorsal, lateroposterior, gelatinosus, reuniens, paraventricular and intralaminar nuclei. In some cases, remarkably large immunoreactive puncta were abundant in the lateral geniculate (Fig. 5D ), ventrobasal and other nuclei; these profiles were often associated with the margins of cell bodies and rarely appeared as varicose swellings along axons. In the ep~thalamus and pretectum. immunoreactivity was present in neurons in lateral habenula, but not medial habenula, and also relatively intense in cells in the olivary pretectal nucleus and diffusely in the anterior pretectat nucleus (Fig. 5B) . In the hypothalamus, most regions were more lightly stained than thafamus. with the exception that high fcvels of m3 immunoreactivily were present in neurons in the lateral mammillary nucleus (Fig. 5F ) and in neuropil in the premammiflary nucleus, and moderate levels were present in neurons in the paraventricular nucleus, lateral hypothalamus and diffusely in the ~entromed~al nucfeus. Neurons in the zona incerta were also immunoreactive.
Brainstem. Because the hindbrain regions exhibited generally higher levels of background staining than in forebrain, uncertainty exists regarding many nuclei. The background staining was not due to m3 antibody, since it occurred in the controls even when the primary antibody was omitted. The following structures were none the fess consistently enriched in m3 immunoreactivity compared to controls, and the possibility that other nuclei express few levels of m3 ilnmunoreactivity cannot be dismissed. Immunoreactivity in the midbrain was localized to a dense plexus of fibers and puncta in the neuropil in the superficial layer of superior colliculus, and to more weakly stained neuropil in deeper layers extending to immunoreactive, and scattered neurons throughout the central gray (Fig. 6C ). In the pontine nuclei the reticular formation were more darkly stained than (Fig. 6A, B) , neurons and neuropil were both densely in controls. In cerebellum, medulla and spinal cord, 
DG). (B) Higher magnification of m3 in CA1 and dcntatc gyrus is shown in thts photomontage
Note the laminat pattcrr~s with immunoreactivity localized in cell bodies of pyramidal neurons (p). and relatively denw reaction product in the neuropil in the deeper aspects of the stratum radiatum (r), stratum lacunosum moleculare (l-m) and stratum trriens IO). The dentate gyrus. shown below the hippo~mpai fissure (dashed line). also expresses dense m? imm~~noreacti~,~t~. Granule cells (gc) express low lcvcls of m3, but the receptor is present in the neuropil in the molecular layer-(mo) UKI hilus (hi) and 0cc~tsiona1 non-pyramtdal neurons (arrow), (C) The entorhinal cortex expresres relatively high levels of m3 immunoreactivity compared to other corticat regions. The receptor is enriched in the supcrlkial rrmlecular layer, stellatc neurons in layer 11, and both neurons and neuropil in deep layers. (D-F) Coronal sections through the medial septum (MS) and diagonal band of Broca (DB), prccessed for m3 immunoreactivity (D), conti-ol (E) or choline acetyitransferase immunoreactivity (F) " Note the similar distributions of m3 immunoreactiviiy and cholinergic neurons, although the ncuropil is more immunoruactivc with the m3 antibody. The control section was processed without primary antibody, and shows low levels of background staining in man:~ neurons. S&c bar-s = 200 jtrn (A E). background staining was too high to evaluate, with the exception of the spinal trigeminal nucleus, which was enriched in fine fibers, and neurons in the cranial and spinal somatic motor nuclei also appeared weakly immunoreactive.
Comparison of m 3 immunoreactivity and M3 binding
The regional distributions of m3 immunoreactivity and M3 binding to [3H]4-DAMP (in the presence of pirenzepine and AF-DX 116) were compared in matched sections from different animals (Fig. 2) . Results of M3 binding were described in detail previously and are uncorrected for tritium quenching. 43 The general distributions of both markers were similar, with relatively dense levels of staining or binding in neocortex, hippocampus, striatum, anterior thalamic nuclei, superior colliculus and pontine nuclei.
Also. the markers were both present at moderate levels in lateral geniculate, medial geniculate, hypothalamus and periaqueductal gray, and they were both found at much lower levels in white matter pathways, such as corpus callosum, internal capsule, cerebral peduncle and medial lemniscus. There were also some significant differences in the distributions of m3 immunoreactivity versus M3 binding. For example, frontoparietal cortex was relatively enriched in M3 binding compared to the adjacent cingulate cortex, while the opposite pattern was found with m3 immunoreactivity. Also, laminar differences were marked in hippocampus, where M3 was most dense in stratum oriens and stratum radiatum of CA1 with little binding in CA3, while m3 immunoreactivity was most dense in the stratum lacunosum moleculare and deep radiatum of CA3. However, minute comparisons were not attempted because of inherent limitations such as use of different animals for each marker (because of the need to use unfixed tissue for autoradiography and fixed tissue for immunocytochemistry), and likely differences in sensitivity and spatial resolution attainable with each method.
DISCUSSION
There are several principal findings of the present study. First, the low levels of m3 muscarinic acetylcholine receptor protein in widespread regions of rat brain have confirmed earlier immunoprecipitation studies. Second, the light microscopic immunocytochemical findings also demonstrate a wide distribution of m3 immunoreactivity, and indicate that the protein is localized in specific cells and subcellular sites, complementing and extending previous studies of m3 mRNA. Third, the general distributions of m3 receptor protein visualized by imunocytochemistry and M3 binding sites by autoradiography are similar but not identical, indicating that the two markers may not be equivalent. The findings clarify the localization of m3 receptor, its correspondence to the pharmacologically defined binding site, and suggest a variety of functional implications for m3 in muscarinic cholinergic neurotransmission in the central nervous system.
Abundance ofm3 and other muscarinic receptor proteins in rat brain
Immunoprecipitation studies have been used to determine the proportion of m3 and other muscarinic receptor subtypes in dissected regions of rat brain. In our previous studies using 1 nM ['H]NMS to label solubilized receptors, we were unable to recover significant levels of m3. 16 In the present study, saturation binding analysis using the native brain receptor population demonstrated an equilibrium dissociation constant of 0.30, suggesting that solubilized receptors were incompletely (about 75%) labeled by 1 nM ['H]NMS. Indeed, using higher concentrations of ligand (10nM) we now recover m3 in widespread regions of brain. Our results indicate that m3 is present at low levels, accounting for only about i-10% of the total population of muscarinic receptors solubilized in the regions studied. However, we are cautious about interpreting these values, because despite their statistical significance, they are only about 20-SO% greater than control immunoprecipitates due to the higher levels of background with 10 nM ['HJNMS. The values more accurately reflect the upper limits of m3 contribution, given the saturating ligand concentration employed and the quantitative recovery of the receptors. None the less, our findings are in excellent agreement with immunoprecipitation studies of Wall et al.'* using a peptide antibody directed to the C-terminus of m3. Potcntially, methodological problems could result in apparently lower levels of m3 than are actually present in tissues, For instance, reduced solubilization of m3 compared to other subtypes (e.g. due to possible differential subcellular compartmentation) or loss of antigenic sites (e.g. due to proteolytic cleavage or post-translational modifications) are theoretically possible. However, radioligand binding studies using tissue homogenates and sophisticated kinetic analyses,r6 and autoradiographic binding studiesq3 both generally agree with immunoprecipitation studies, and neither approach depends on solubilization of receptors. Also, since our polyclonal antibodies are directed to a variety of epitopes on the large i3 loop, and the polyclonal antibodies of Wall et 01.~~ recognize the C-terminus, loss of both of these antigenie regions is unlikely.
Improved recovery of m3 in our immunoprecipitation assay using 10 nM [3H]NMS prompted a reanalysis of the entire family of ml-m5 receptors using a panel of subtype-specific antibodies (Table 2 ). Contributions of ml and m2 receptors to the total receptor populations were comparable to the results of our previous immunoprecipitation studies, 16 as well as those of Wolfe and col1eagues.'8.37 However, the levels of m4 in each region are about 15% higher than we found previously, suggesting that this subtype was incompletely labeled with lower concentrations of radiolabel. The m4 receptor now appears to be the predominant subtype in striatum and accounts for almost a third of the total muscarinic receptors in cortex and thalamus. These results are in excellent agreement with other recent immunoprecipitation studies. 42 The m5 receptor also appeared to be recovered more efficiently in the present study, although present at very low levels throughout the brain. As discussed above for m3, we are unsure about the lower limits of measurable m5 receptors and the meaningfulness of these results. Our upper limit estimates of 5-6% of total receptors in each region are somewhat higher than the levels of m5 reported by Yasuda et aL4' (~2%) using different antibodies and techniques. The widespread distribution of mS protein is somewhat surprising, given the limited distribution of mS mRNA found by in sifu hybridization studies.34,41 However, differences in the sensitivity of the methods may explain this mismatch, since m5 mRNA is detectable throughout the brain using more sensitive polymerase chain reaction methods. 40 Other possible explanations are differences in turnover, stability or subcellular distribution of the mRNA versus protein. Direct localization of m5 receptor protein will be necessary to address these issues, although our attempts using immunocytochemistry have not been successful and specific ligands for autoradiographic binding are not available.
ImmunocJ;tochemical localization of m 3
Antibodies specific to m3 have provided the first opportunity to determine the precise distribution of this subtype using immun~ytochemistry.
The expression of m3 is widespread, consistent with the immunoprecipitation studies. The cellular localization of m3 protein also agrees well with in situ hybridization studies of m3 mRNA, including a close match in olfactory bulb. regions and layers of the cortex, hippocampal formation, thalamic nuclei, subthalamus. posterior hypothalamus.
superior colliculus, central gray and pontine nuclei.' Although m3 mRNA is expressed in widespread regions of the brainstem, we are unsure of the distribution of protein because of problems with higher levels of background immu~oreactivity in the hindbrain. The agreement between immunocytochemical and in situ hybridization approaches substantiates the distribution of m3, and implicates this subtype in a wide variety of central nervous system processes.
The light microscopic appearance of m3 suggests that this receptor may be compartmentalized in subcellular sites. For example. immunoreactivity in somata and proximal dendrites of neurons is consistent with postsynaptic distributions. The diffuse or punctatc appearance of the immunoreactivity, as occurs in the molecular layer of cortex. hippocampus, striatum and many thalamic nuclei, is consistent with either presynaptic localization in terminals or postsynaptic localization in dendritic spines. In structures with little or no intrinsic expression of m3 mRNA, such as striatum,' presynaptic localization in the terminals of extrinsic afferent fibers may be more likely. In fact, we have recently confirmed the prcsynaptic localization of m3 in striatum by direct observation using immunoelecton microscopy.'0 Presynaptic muscarinic receptors, with M3-like binding preferences, regulate neurotransmitter release in striaturn, as well as in hippocampus and amygdala.'".zY." Localization of m3 immunoreacti~lity at the ultrastructural level will be important to identify the preand postsynaptic distribution of this subtype in other regions.
Although presynaptic muscarinic receptor subtypes are well known to regulate the release of acetylcholine. iZ.Z".23~27~28~33 the molecular identity of the autoreceptorfs) in many brain regions is unknown. Several pharmacological and lesion studies have implicated M2 as an inhibitory presynaptic site modulating acetylcholine release in cortex, hippocampus and striatum.'Z~2'~'".Zx The m2 protein may correspond to some of these binding sites, since the mRNA' and proteinI are expressed at high levels in basal forebrain and in cholinergic neurons in striatum,',"' Moreover, immunoelectron microscopic studies have directly localized m2 protein to prcsynaptic sites which are likely to be cholinergic in necortex2" and striatum.'O Other subtypes may also be autoreceptors. since pharmacological studies have found that Ml sites in basal forebrain'" and M3 sites in hippocampus *O inhibit acetylcholine release. MI sites in cortex stimulate release as well.'7 The m3 protein is a candidate for a muscarinic autoreceptor in cortex and hippocampus on both pharmacological and anatomical grounds. That is, its intermediate binding affinities for selective compounds are compatible with the varied pharmacologies reported for autoreceptors. The m3 mRNA" and, as shown here, the tn3 protein are expressed in basal forebrain neurons which may project to cortex and hippocampus. However. the basal forebrain consists of heterogeneous ~vtil populations, and whether m3 is expressed in the cholinergic neurons and also transported to terminal sites is unknown. Future studies to co-localize each receptor protein in cholinergic nerve terminals will be useful to clarify the molecular identity of the autoreceptors.
Despite the widespread distribution of m3, localization of this receptor suggests that it may play a special role in limbic processes. For example, among cortical areas, the limbic regions display the most intense m3 immunoreactivity.
including cingulate, retrosplenial, entorhinal, insular and piriform coriex. Also, the hippocampus and amygdala are enriched in m3. Moreover, the limbic nuclei in the anterior thalamu?. and the connectionally related neurons in the mnmmillary nuclei and posterior hypothalamus exhibit dense m3 immunoreactivity, Interestingly. many of these structures have been implicated in memory processes, and the diencephalic nuclei are also important in behavioral state control. A role for m3 in these cholinergic functions may have important clinical implications for targeting subtypespecific drugs in patients with memory and sleep disorders.
Are nz3 and M 3 the ,mnze receptor?
The immunocytochemical distribution of m3 was widespread in rat brain and generally consistent with the autoradiograph~c localization of M3. The most striking similarities were noted in deep endopiriform and insular cortex, striatum, anterior thalamic nuclei, superior colliculus, periaqueductal gray and pontine nuclei. These results corroborate predictions made previously by Zubieta and Frey.4' who selected these structures as the regions in which the labeled sites are most likely to correspond to m3 protein. As discussed by these authors previously, sites labeled by ['HICDAMP in the presence of pirenzepine and AF-DX 116 are predicted to include residual m I, m2 and m4 receptors in regions where these proteins are subs~ntially higher than m3. However, those sites with the most enriched [jH]4-DAMP binding, as determined by the ratio of residual binding in the presence or absence of the antagonists to block non-M3 rcccptors, are most likely to reflect m3. The correspondence of the markers in the aforementioned regions provides evidence that ligand binding sites labeled by these conditions are comprised mainly of m3 protein.
There are also notable differences in the distributions of m3 immunoreactivity and M3 binding sites in key regions and lamina of cortex and hippo-campus. There are several possible explanations for these discrepancies. First, each probe may gain access to different populations of m3 receptors. Ligand binding is believed to reside within the transmembrane domains," while the antibodies react with the putative third cytoplasmic 10op.'~ Thus, ligands may bind to receptors in which the antibody binding sites are unavailable, e.g. due to post-translational modifications or interactions with other membrane proteins. Similarly, antibodies may detect receptors in synthetic or degradative pathways, or other discrete subcellular compartments in which the proteins are not functional or capable of binding ligands. A second factor possibly contributing to areas of mismatch is that M3 binding patterns have not been corrected for tritium quenching. This is a nonuniform process and results in an apparent reduction of isotope content in white matter. Thirdly, potential problems with the specificity of either probe may also add to differences between m3 and M3. As discussed above, this is a recognized problem for M3 binding, since even in the presence of pirenzepine and AF-DX I16 residual binding to other subtypes is expected."' Residual binding of ['H]4-DAMP to ml could in part explain the mismatch between m3 and M3 in both cortex and hippocampus, since ml is abundant in these structures and the regional and laminar patterns of M3 binding appears nearly identical to that of m1.16 Because m3 is present at low levels and barely detectable with our antibodies, we also cannot entirely exclude the possibility that m3 antibodies may cross-react with other brain proteins, despite their characterization by immunoprecipitation" and Western blotting analysis."' Regardless of the explanation, the m3/M3 mismatch in cortex and hippocampus suggests thal m3 protein and M3 binding sites labeled with these conditions are not entirely equivalent.
A correspondence between the m3 gene/protein and the M3 binding site defined pharmacologically has been suggested in several important reviews,8,",'* and such a relationship is implicit in nomenclature recommended by the IUPHAR muscarinic committee.39 Using the most selective probes available for both the m3 protein and the M3 binding site, we have shown that the markers may overlap, but imprecisely. Other pharmacologically defined sites are also likely to be composites of multiple receptor proteins given the well recognized problems with limited selectivity of available ligands4.6,35 and the presence of multiple receptor proteins in most brain regions'6,4' and peripheral tissues.s For these reasons, we recommend that investigators use strict definitions for molecular (ml-m5) and pharmacological (M I-M4) classifications. Although reconciliation of dual classification systems would be ideal, until direct evidence proves otherwise, identities between these schemes should not be presumed.
CONCLUSIONS
The present study demonstrates that m3 receptor protein is present at low but measurable levels throughout discrete neuronal populations in the forebrain and upper brainstem. There is a close but imprecise relationship between m3 receptor detected by antibodies and M3 receptor detected by ligand autoradiography, suggesting that molecular and pharmacological classification schemes are not equivalent. However, because of the limitations inherent to each technique and the low abundance of this subtype, the receptors can be localized with the greatest certainty to structures that show agreement between m3 immunoreactivity and M3 binding. These structures include several Iimbic regions of cortex and thalamus. striatum. superior colliculus and pontine nuclei. This distribution suggests that m3jM3 mediates a variety of cholinergic functions, including possible roles in learning, memory, and motor and behavioral state control, and that this subtype is potentially a valuable target for therapeutic drugs for a variety of neurological and psychiatric disorders.
